Newly Eligible 340B Hospitals Advised to Apply Early
OPA Announces July 28 Webinar on 340B Enrollment for New Hospital Types
Emotions Surface During 340B Conference Session on Orphan Drugs
Preliminary Data Show 9.4% Decline in 340B Prices
OPA Warned BMS Against Offsetting Repayments to Providers
Enrollment for New Categories of 340B Providers to Begin Aug. 2
PSSC Announces New "Peer to Peer" Network
Rx School Dean Calls for Pharmacists to Fill Some Roles of M.D.s
Standing-Room Only at Introduction to 340B Session
House Votes to Lift 340B Orphan Drug Prohibition for Children's Hospitals
Drug Firms Ask U.S. Supreme Court to Hear Santa Clara 340B Case
Multiple Contract Pharmacy Guidelines Are Drawing Considerable Interest
Mitchell and Burch to Receive 340B Coalition's Lifetime Achievement Award
Sebelius Pledges to Provide an Extra $25 Million for AIDS Assistance
SNHPA Expresses Condolences to Friend of Safety-Net Hospital Community
House Approves AMP Clarification in Supplemental War Funding Bill
Medicines Company Offers Retroactive Discounts on Angiomax and Cleviprex
July 2, 2010 - Drug manufacturer Medicines Company is inviting 340B covered entities to seek refunds of overcharges on its two marketed drugs, the anti-coagulant Angiomax and the calcium channel blocker Cleviprex, retroactive to the date of the company's entry into the 340B program last December.
In a notification to 340B providers on its Web site, the drug company tells covered entities they can submit signed refund forms posted on the site to seek rebates for purchases as far back as Dec. 21, 2009. Forms must be submitted by August 31, 2010.
It is unclear from the notice whether the purpose of the refunds is to pay covered entities for deeper 340B discounts than those they might have already received since late last year, to pay for overcharges to covered entities that received no 340B discounts during that period, or both. A safety-net hospital that bought the products through its 340B account reported to the Monitor that it was told by Medicines Company that it was not eligible for a rebate and that rebates are only available for purchases made through a GPO contract. Safety Net Hospitals for Pharmaceutical Access, which represents hospitals that participate in the drug discount program, says is continuing to seek clarity on this matter.
The manufacturer expects covered entities to include the following information on the refund form: (1) the invoice number, date of purchase, and purchase price relating to the product for which the refund is sought; (2) the number of boxes of each NDC purchased for appropriate use under the 340B program; and (3) the name of the wholesaler from which the product was purchased.
Medicines Company will inform covered entities in a separate communication when their refunds have been approved. Refunds of overpayments will be processed by Apexus/340B Prime Vendor Program as credits against future purchases, applied to the covered entity's 340B account with its wholesaler. It does not appear that cash refunds will be made available to covered entities.
Refund forms must be emailed to 340Bprogram@themedco.com or mailed to Nancy Navin at the company's physical address at 8 Sylvan Way, Parsippany, N.J. 07054. Inquiries should be addressed to nancy.navin@themedco.com or (973) 290-6056.
